Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies
Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”)...
IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement
To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing...
Hitachi and Axcelead DDP Launch Manufacturing Process Development Support Service for Cell Therapy and Gene Therapy
Supporting optimization of product development and manufacturing with automation and quality assessment Tokyo, December 15, 2021 —...
Axcelead Drug Discovery Partners was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED)* in a program for “Drug Discovery Seeds Development”
Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has supported 24 research projects aiming at new drug development...
xFOREST Therapeutics, Axcelead DDP and Kyowa Kirin Initiated an Collaboration in RNA Structures Targeted Drug Discovering
Tokyo, Japan, October ##, 2021 — xFOREST Therapeutics Co., Ltd. (Headquarter: Kamigyo-ku, Kyoto, Japan, President and CEO:...
Axcelead DDP participates in “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan”, as a joint research institute
We are pleased to announce that Axcelead Drug Discovery Partners Inc., (Headquarters: Fujisawa, Kanagawa, JAPAN, CEO: Yoshinori...